Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer

BACKGROUND: Aberrant activation of the intracellular tyrosine kinase Src has been implicated as a mechanism of acquired chemotherapy resistance in metastatic colorectal cancer (mCRC). Here, the oral tyrosine kinase Src inhibitor, dasatinib, was investigated in combination with FOLFOX and cetuximab....

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Clin Cancer Res
मुख्य लेखकों: Parseghian, Christine M., Parikh, Nila U., Wu, Ji Yuan, Jiang, Zhi-Qin, Henderson, Laura, Tian, Feng, Pastor, Brice, Ychou, Marc, Raghav, Kanwal, Dasari, Arvind, Fogelman, David R., Katsiampoura, Anastasia D., Menter, David G., Wolff, Robert A., Eng, Cathy, Overman, Michael J., Thierry, Alain R., Gallick, Gary E., Kopetz, Scott
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2017
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540760/
https://ncbi.nlm.nih.gov/pubmed/28280091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-3138
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन